Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma

Neuro-Oncology

Volumn 12, Issue 12, 2010, Pages 1244-1256

  Teider, Natalia ^a   Scott, Deborah K ^a   Neiss, Adrianne ^a   Weeraratne, S Dilhan ^a   Amani, Vladimir M ^a   Wang, Yifei ^a   Marquez, Victor E ^b   Cho, Yoon Jae ^a   Pomeroy, Scott L ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Deazaneplanocin; Jagged1; Neuralized1; Notch; Tumor suppressor

Indexed keywords

JAGGED1; NOTCH RECEPTOR; TRANSCRIPTION FACTOR HES 1;

APOPTOSIS; ARTICLE; BRAIN TISSUE; CELL DEATH; CELL DIFFERENTIATION; CHROMOSOME 10Q; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE LOSS; GENETIC TRANSFECTION; HETEROZYGOSITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MEDULLOBLASTOMA; NEURALIZED1 GENE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ADOLESCENT; ADULT; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; CEREBELLUM; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEDULLOBLASTOMA; MEMBRANE PROTEINS; PHENOTYPE; PROMOTER REGIONS, GENETIC; RECEPTORS, NOTCH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES;

EID: 78650154699     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq091     Document Type: Article

References (49)

1. Kim JY, Nelson AL, Algon SA, et al. Medulloblastoma tumorigenesisdiverges from cerebellar granule cell differentiation in patched heterozygousmice. Dev Biol. 2003;263:50-66.
2. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of centralnervous system embryonal tumour outcome based on gene expression.Nature. 2002;415:436-442.
3. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene ortumour suppressor? Nat Rev Cancer. 2003;3:756-767.
4. Solecki DJ, Liu XL, Tomoda T, Fang Y, Hatten ME. Activated Notch2 signalinginhibits differentiation of cerebellar granule neuron precursors bymaintaining proliferation. Neuron. 2001;31:557-568.
5. Irvin DK, Zurcher SD, Nguyen T, Weinmaster G, Kornblum HI.Expression patterns of Notch1, Notch2, and Notch3 suggest multiplefunctional roles for the Notch-DSL signaling system during brain development.J Comp Neurol. 2001;436:167-181.
6. Roy M, Pear WS, Aster JC. The multifaceted role of Notch in cancer.Curr Opin Genet Dev. 2007;17:52-59.
7. Lee SH, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of NOTCH1, 2,3 and 4 genes in common solid cancers and acute leukemias. Apmis.2007;115:1357-1363.
8. Fan X, Mikolaenko I, Elhassan I, et al. Notch1 and notch2 have oppositeeffects on embryonal brain tumor growth. Cancer Res.2004;64:7787-7793.
9. HallahanAR, Pritchard JI,Hansen S, et al. TheSmoA1mousemodel revealsthat notch signaling is critical for the growth and survival of sonichedgehog-induced medulloblastomas. Cancer Res. 2004;64:7794-7800.
10. Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletesstem-like cells and blocks engraftment in embryonal brain tumors.Cancer Res. 2006;66:7445-7452.
11. Nakamura H, Yoshida M, Tsuiki H, et al. Identification of a humanhomolog of the Drosophila neuralized gene within the 10q25.1malignant astrocytoma deletion region. Oncogene. 1998;16:1009-1019.
12. Scott DK, Straughton D, Cole M, Bailey S, Ellison DW, Clifford SC.Identification and analysis of tumor suppressor loci at chromosome10q23.3- 10q25.3 in medulloblastoma. Cell Cycle. 2006;5:2381-2389.
13. Le Borgne R, Bardin A, Schweisguth F. The roles of receptor and ligandendocytosis in regulating Notch signaling. Development. 2005;132:1751-1762.
14. Commisso C, Boulianne GL. The NHR1 domain of neuralized bindsdelta and mediates delta trafficking and Notch signaling. Mol BiolCell. 2007;18:1-13.
15. Yeh E, Dermer M, Commisso C, Zhou L, McGlade CJ, Boulianne GL.Neuralized functions as an E3 ubiquitin ligase during Drosophila development.Curr Biol. 2001;11:1675-1679.
16. Timmusk T, Palm K, Belluardo N, Mudo G, Neuman T. Dendriticlocalization of mammalian neuralized mRNA encoding a protein withtranscription repression activities. Mol Cell Neurosci. 2002;20:649-668.
17. Keles GE, Berger MS, Srinivasan J, Kolstoe DD, Bobola MS, Silber JR.Establishment and characterization of four human medulloblastomaderivedcell lines. Oncol Res. 1995;7:493-503.
18. He XM, Wikstrand CJ, Friedman HS, et al. Differentiation characteristicsof newly established medulloblastoma cell-lines (D384 Med, D425Med, and D458 Med) and their transplantable xenografts. Lab Invest.1991;64:833-843.
19. Langdon JA, Lamont JM, Scott DK, et al. Combined genome-wide allelotypingand copy number analysis identify frequent genetic losseswithout copy number reduction in medulloblastoma. GenesChromosomes Cancer. 2006;45:47-60.
20. Lindsey JC, Lusher ME, Anderton JA, et al. Identification of tumourspecificepigenetic events in medulloblastoma development by hypermethylationprofiling. Carcinogenesis. 2004;25:661-668.
21. Jiang X, Tan J, Li J, et al. DACT3 is an epigenetic regulator of Wnt/betacateninsignaling in colorectal cancer and is a therapeutic target ofhistone modifications. Cancer Cell. 2008;13:529-541.
22. Weeraratne SD, Valentine M, Cusick M, Delay R, Van Houten JL.Plasma membrane calcium pumps in mouse olfactory sensoryneurons. Chem Senses. 2006;31:725-730.
23. Caslini C, Capo-chichi CD, Roland IH, Nicolas E, Yeung AT, Xu XX.Histone modifications silence the GATA transcription factor genes inovarian cancer. Oncogene. 2006;25:5446-5461.
24. Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histoneH3 lysine 27 trimethylation independent of promoter DNA methylation.Nat Genet. 2008;40:741-750.
25. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption ofPolycomb-repressive complex 2-mediated gene repression selectivelyinduces apoptosis in cancer cells. Genes Dev. 2007;21:1050-1063.
26. Jackson PK, Eldridge AG, Freed E, et al. The lore of the RINGs: substraterecognition and catalysis by ubiquitin ligases. Trends Cell Biol.2000;10:429-439.
27. Sanchez-Diaz PC, Burton TL, Burns SC, Hung JY, Penalva LO. Musashi1modulates cell proliferation genes in the medulloblastoma cell line Daoy.BMC Cancer. 2008;8:280.
28. Koutelou E, Sato S, Tomomori-Sato C, et al. Neuralized-like 1 (Neurl1)targeted to the plasma membrane by N-myristoylation regulates theNotch ligand Jagged1. J Biol Chem. 2008;283:3846-3853.
29. Miranda TB, Jones PA. DNA methylation: the nuts and bolts of repression.J Cell Physiol. 2007;213:384-390.
30. Pietersen AM, van Lohuizen M. Stem cell regulation by Polycomb repressors:postponing commitment. Curr Opin Cell Biol. 2008;20:201-207.
31. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683-692.
32. Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW.5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferaseand histone H3 K9 di-methylation levels are linked totumor suppressor gene reactivation. Oncogene. 2007;26:77-90.
33. Nguyen CT, Weisenberger DJ, Velicescu M, et al. Histone H3-lysine 9methylation is associated with aberrant gene silencing in cancer cellsand is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res.2002;62:6456-6461.
34. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-widemapping of Polycomb target genes unravels their roles in cell fate transitions.Genes Dev. 2006;20:1123-1136.
35. Lee TI, Jenner RG, Boyer LA, et al. Control of developmental regulatorsby Polycomb in human embryonic stem cells. Cell. 2006;125:301-313.
36. Boyer LA, Plath K, Zeitlinger J, et al. Polycomb complexes repress developmentalregulators in murine embryonic stem cells. Nature.2006;441:349-353.
37. Northcott PA, Nakahara Y, Wu X, et al. Multiple recurrent geneticevents converge on control of histone lysine methylation in medulloblastoma.Nat Genet. 2009;41:465-472.
38. Schuebel KE, Chen W, Cope L, et al. Comparing the DNA hypermethylomewith gene mutations in human colorectal cancer. PLoS Genet.2007;3:1709-1723.
39. Vollrath B, Pudney J, Asa S, Leder P, Fitzgerald K. Isolation of a murinehomologue of the Drosophila neuralized gene, a gene required for axonemalintegrity in spermatozoa and terminal maturation of themammary gland. Mol Cell Biol. 2001;21:7481-7494.
40. Ruan Y, Tecott L, Jiang MM, Jan LY, Jan YN. Ethanol hypersensitivityand olfactory discrimination defect in mice lacking a homologof Drosophila neuralized. Proc Natl Acad Sci USA. 2001;98:9907-9912.
41. Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR,Gudkov AV. A systematic search for downstream mediators oftumor suppressor function of p53 reveals a major role of BTG2 insuppression of Ras-induced transformation. Genes Dev. 2006;20:236-252.
42. Farioli-Vecchioli S, Tanori M, Micheli L, et al. Inhibition of medulloblastomatumorigenesis by the antiproliferative and pro-differentiative genePC3. FASEB J. 2007;21:2215-2225.
43. Park S, Lee YJ, Lee HJ, et al. B-cell translocation gene 2 (Btg2) regulatesvertebral patterning by modulating bone morphogenetic protein/smadsignaling. Mol Cell Biol. 2004;24:10256-10262.
44. Takeuchi T, Adachi Y, Sonobe H, Furihata M, Ohtsuki Y. A ubiquitinligase, skeletrophin, is a negative regulator of melanoma invasion.Oncogene. 2006;25:7059-7069.
45. Koo BK, Lim HS, Song R, et al. Mind bomb 1 is essential for generatingfunctional Notch ligands to activate Notch. Development.2005;132:3459- 3470.
46. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stemcell in human brain tumors. Cancer Res. 2003;63:5821-5828.
47. Ascano JM, Beverly LJ, Capobianco AJ. The C-terminal PDZ-ligand ofJAGGED1 is essential for cellular transformation. J Biol Chem.2003;278:8771-8779.
48. Weller M, Krautler N, Mantei N, Suter U, Taylor V. Jagged1 ablationresults in cerebellar granule cell migration defects and depletion ofBergmann glia. Dev Neurosci. 2006;28:70-80.
49. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies fivemedulloblastoma subtypes with distinct genetic profiles, pathway signaturesand clinicopathological features. PLoS One. 2008;3:e3088.